Drug
doxecitine and doxribtimine
doxecitine and doxribtimine is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(67%)
Phase Distribution
Ph phase_2
2
67%
Phase Distribution
0
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 2Efficacy & side effects
2(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Other(1)
Detailed Status
Recruiting1
Active, not recruiting1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 22 (100.0%)
Trials by Status
recruiting133%
active_not_recruiting133%
unknown133%
Recent Activity
2 active trials
Showing 3 of 3
active_not_recruitingphase_2
An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency
NCT03845712
unknown
Doxecitine and Doxribtimine-Expanded Access
NCT06590493
recruitingphase_2
Doxecitin and Doxribthymine in Adult Subjects With Thymidine Kinase 2 (TK2) Deficiency
NCT06754098
Clinical Trials (3)
Showing 3 of 3 trials
NCT03845712Phase 2
An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency
NCT06590493
Doxecitine and Doxribtimine-Expanded Access
NCT06754098Phase 2
Doxecitin and Doxribthymine in Adult Subjects With Thymidine Kinase 2 (TK2) Deficiency
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3